Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

neurotrophic keratopathy - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

neurotrophic keratopathy

MONDO:0015290

Also known as:neurotrophic keratitis

Find Clinical TrialsTrials

Overview

Neurotrophic keratopathy is a rare degenerative disease of the cornea characterized by reduction or loss of corneal sensitivity that can be asymptomatic or present with red-eye and, during the early stages of the disease, a minor decrease in visual acuity. It eventually leads to loss of vision.

Treatments1 FDA approved

Clinical Trials13 registered · 6 recruiting

Diagnosis

Biomarker and diagnostic research for neurotrophic keratopathy has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for neurotrophic keratopathy, including CENEGERMIN-BKBJ (OXERVATE, approved 2018). An additional 6 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

13 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 4 PHASE4, 1 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06975748](https://clinicaltrials.gov/study/NCT06975748)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 9:41 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:137596

GARD

Genetic and Rare Diseases Info Center

GARD:19878

Questions for Your Care Team

→What are the benefits and potential side effects of OXERVATE for managing neurotrophic keratopathy?
→Are any of the 13 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-Dihydroxy-docosa-4,7,11,13,15,19-hexaenoate	sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-Dihydroxy-docosa-4,7,11,13,15,19-hexaenoate	Anida Pharma Inc.	2025	—	Designated
lacripep	lacripep	TearSolutions Inc.	2024	—	Designated
allogeneic human blood serum	allogeneic human blood serum	Allovision, LLC	2024	—	Designated
exosomes purified from primed human bone marrow derived mesenchymal stem cells and methacrylated hyaluronic acid	exosomes purified from primed human bone marrow derived mesenchymal stem cells and methacrylated hyaluronic acid	Pandorum Technologies, Inc.	2023	—	Designated
Pigment Epithelium Derived Factor derived short peptide (Ac-Ser-Leu-Gly-Ala-Glu-Gln-Arg-Thr-Glu-Ser-Ile-Ile-His-Arg-Ala- Leu-Tyr-Tyr-Asp-Leu-Ile-Ser-Ser-Pro-Asp-Ile-His-Gly-Thr-NH2)	Pigment Epithelium Derived Factor derived short peptide (Ac-Ser-Leu-Gly-Ala-Glu-Gln-Arg-Thr-Glu-Ser-Ile-Ile-His-Arg-Ala- Leu-Tyr-Tyr-Asp-Leu-Ile-Ser-Ser-Pro-Asp-Ile-His-Gly-Thr-NH2)	BRIM Biotechnology	2022	—	Designated
(1S, 4R, 5R, 7S)-3, 4-dibenzyl-2-oxo-6, 8-dioxa- 3-azabyciclo [3.2.1] octane-7-carboxylic acid-L-lysine	(1S, 4R, 5R, 7S)-3, 4-dibenzyl-2-oxo-6, 8-dioxa- 3-azabyciclo [3.2.1] octane-7-carboxylic acid-L-lysine	Recordati Rare Diseases, SARL	2018	—	Withdrawn

Research Type	Count	% of Total
Research summaries	38	25%
Patient case studies	38	25%
Laboratory research	26	17%
Clinical study results	21	14%
Disease patterns and progression	13	9%
Testing and diagnosis research	7	5%
Other research	4	3%
New treatment approaches	3	2%

Kisho

neurotrophic keratopathy

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

[Research status of topical insulin therapy for neurotrophic keratopathy].

neurotrophic keratopathy

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

[Research status of topical insulin therapy for neurotrophic keratopathy].